Save over 93% with generic version of Palbace and 80% with brand from Pfizer today at insulinhub. Palbace is also known internationally as Primcyv, and Reampla made by Pfizer.
Palbace, Reampla and Primcyv from Pfizer are manufactured at: either their factory in Germany or the USA:
M/s. Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg; Mooswaldallee 1 Freiburg - 79090 NA (Germany). or their factory in the United States
Palbace (palbociclib) is an oral medication used primarily in the treatment of certain types of breast cancer. It is classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor and works by interfering with the cancer cell cycle, thereby slowing down or stopping the growth of cancer cells.
Product Highlights
Palbace is indicated for:
Treatment of HR-positive, HER2-negative breast cancer in combination with an aromatase inhibitor or tamoxifen.
Used as first-line therapy or in patients who have received prior hormonal therapy.
Key Ingredient
Palbociclib
Key Benefits
Enhances the efficacy of hormonal therapies.
Clinical trials have shown improved progression-free survival rates in patients.
Specifically targets cancer cell mechanisms, potentially leading to fewer side effects compared to traditional chemotherapy.
Direction of Use
Typically administered at a dose of 125 mg once daily for 21 days, followed by a 7-day break. Dosage may vary based on the treatment plan and individual tolerance.
Take with or without food, preferably at the same time each day to maintain consistent levels in the bloodstream.
Palbace recommended dose modifications for adverse reactions:
Dose level
Dose
Recommended dose
125 mg/day
First dose reduction
100 mg/day
Second dose reduction
75 mg/day*
* If a dose reduction below 75 mg/day is necessary, the treatment should be discontinued.
Safety Concerns
Common side effects include neutropenia (low white blood cell counts), fatigue, nausea, diarrhea, and rash.
Regular blood tests are required to monitor blood counts and liver function during treatment.
Avoid Palbace (Palbociclib) If
You have a known hypersensitivity to palbociclib or any of its components.
Not advised for patients with significant liver impairment.
Should be avoided in pregnant or nursing individuals due to potential risks to the fetus or infant.
Avoid in patients taking strong CYP3A inhibitors or inducers that can affect the metabolism of palbociclib.
